Emory University

PHILADELPHIA — The question of who should take aspirin is a complicated one and public messaging on it is sometimes confusing, a speaker said at the Heart in Diabetes CME conference.

Availability of oral anticancer medications has increased greatly during the past decade, offering patients the convenience of fewer appointments, less travel time and targeted treatment within the comfort of their homes.

CHICAGO — Teclistamab continued to demonstrate durable efficacy for patients with relapsed or refractory multiple myeloma, according to results from the phase 1/phase 2 MajesTEC-1 trial.

NEW ORLEANS — In part 2 of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about a nonprofit model for expanding access to diabetes care.

NEW ORLEANS — In the third part of this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about new drugs for substantial weight loss and treatment of obesity-related comorbidities, including type 2 diabetes and liver disease.

NEW ORLEANS — In this video exclusive, James R. Gavin III, MD, PhD, talks with Jamy D. Ard, MD, about the misleading concept of metabolically healthy obesity, its effect of delaying early treatment and the benefit of small weight losses.

CHICAGO — Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.

CHICAGO — Trastuzumab deruxtecan significantly extended PFS and OS among patients with HER2-low metastatic breast cancer, regardless of hormone receptor status, compared with standard of care therapy.

NEW ORLEANS— In part one of this video exclusive, James R. Gavin III, MD, PhD, talks with Anne L. Peters, MD, about using technology in underserved populations to close the diabetes treatment gap.

CHICAGO — Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer, according to study results.